 |
  
Biotech Jobs, Learning Resources, Career Tools
|
|
| ||||||||||||||||||||||||||||||
|  |  Genaera Corporation Announces Presentation/Web Cast at BIO InvestorForumPress Release October 18, 2005 PLYMOUTH MEETING, Pa., October 18, 2005 /PRNewswire-FirstCall/ -- Genaera Corporation will give a presentation at BIO InvestorForum being held October 19-20, 2005 at The Palace Hotel in San Francisco, CA. John A. Skolas, Executive Vice President and Chief Financial Officer, will present at 1:20 PM on Thursday, October 20, 2005. The presentation will review highlights of Genaera's development programs, including EVIZON, the Company's lead development program and first in class anti-angiogenic small molecule for the treatment of "wet" age-related macular degeneration (AMD). Genaera's other development programs, squalamine for cancer, the IL9 antibody and mucoregulator program, including LOMUCIN(TM), will also be discussed. A live web cast of Genaera's presentation will be available at the following address: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=GENR&item_id=1149618. Please connect to the site prior to the conference call to ensure adequate time for any software download that may be needed to hear the web cast. Genaera Corporation is a biopharmaceutical company committed to developing medicines to address substantial unmet medical needs in major pharmaceutical markets. The Company has four products in development for the treatment of eye, cancer and respiratory disorders. EVIZON(TM) (squalamine lactate) is Genaera's lead product in development for ophthalmic indications, specifically "wet" age-related macular degeneration (AMD). Genaera's other programs include: squalamine for the treatment of cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease. This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding preliminary results, future clinical development plans and prospects for Genaera's programs. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "develop," "expect," and "continue," or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to; Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including EVIZON(TM) (squalamine lactate), squalamine, interleukin-9 antibody, or LOMUCIN(TM), may be delayed or not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto. CONTACT: Jennifer Bilotti of Genaera Corporation, +1-610-941-4020; orJonathan Fassberg, ext. 16 (investor inquiries), or Daniel Budwick, ext. 14(media inquiries), both of The Trout Group/BMC Communications,+1-212-477-9007 Web site: http://www.genaera.com/
About hireBio
::
Copyright ::
Privacy
:: Legal
:: Contact |
 |
|
 |
Print
This Page